Corticosteroid Plus Pentoxifylline Is Not Better than Corticosteroid Alone for Improving Survival in Severe Alcoholic Hepatitis (COPE Trial)
- First Online:
- 966 Downloads
Corticosteroids and pentoxifylline reduce short-term mortality in severe alcoholic hepatitis (SAH), but not to the extent desired. Combining both drugs may lead to better survival, but has not yet been studied.
To compare the efficacy of corticosteroids plus pentoxifylline with that of corticosteroids alone in improving survival of SAH patients.
Of the 111 patients screened, 70 patients with SAH (Maddrey discriminant function (MDF) ≥ 32) were enrolled. Patients with active infection, bleeding, renal failure, or pancreatitis were excluded. Treatment was given for four weeks to group A (n = 36; prednisolone 40 mg/day plus pentoxifylline 400 mg thrice/day) and group B (n = 34; prednisolone 40 mg/day). Patients were followed up for 6 months. Data are expressed as median (range) or percentage.
Baseline characteristics of the two groups were similar (MDF group A 78.5 (36.8–140.9), group B 74.9 (45.6–140.2)). Four-week and six-month survival in groups A and B were not significantly different (four-week 72.2 and 73.5%, respectively, p = 1.00; six-month 30.6 and 23.5%, respectively, p = 0.417). At seven days, 55.6% of patients in group A and 64.7% in group B had a Lille score <0.45 (p = 0.473). Six-month survival was significantly higher for patients with a Lille Score <0.45 than for those with a Lille score ≥0.45 (group A 55.5 vs. 0%, p = 0.0006; group B 36 vs. 0%, p = 0.0304). Biological improvement at 28 days was significant for both groups; however, the difference between the groups was not significant.
For patients with severe alcoholic hepatitis, a combination of corticosteroids and pentoxifylline has no additional survival advantage compared with corticosteroids alone.
KeywordsCorticosteroids Lille score Pentoxifylline Severe alcoholic hepatitis
- 7.Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36:480–487.PubMedCrossRefGoogle Scholar
- 10.Rambaldi A, Saconato HH, Christensen E, et al. Systematic review: glucocorticosteroids for alcoholic hepatitis—a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther. 2008;27:1167–1178.PubMedCrossRefGoogle Scholar
- 15.Mc Cullough AJ, O’ Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2022–2036.Google Scholar
- 21.Sidhu SS, Goyal O, Singla M, et al. Pentoxifylline in severe alcoholic hepatitis: a prospective randomized trial. Trop Gastroenterol. 2009;30:S21–S22.Google Scholar
- 28.Mathurin P, Louvet A, Dao T, et al. Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6-month survival: results of the Corpentox trial. Hepatology. 2011;54:81A.Google Scholar
- 32.Singal AK, Bashar H, Anand BS, et al. Graft and patient survival after liver transplantation for alcoholic hepatitis—comparison to alcoholic cirrhosis: exploratory analysis based on UNOS data. Hepatology. 2011;54:162A.Google Scholar